Evidence map›Paper›PMID 27783276›Full record

Trial reportClinical and experimental nephrology2017

Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.

Takao Saito, Masayuki Iwano, Koichi Matsumoto, Tetsuya Mitarai, Hitoshi Yokoyama, Noriaki Yorioka, Shinichi Nishi, Ashio Yoshimura, Hiroshi Sato, Satoru Ogahara and 10 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 1 country.

Takao SaitoProfessor Emeritus, Fukuoka University, and Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka, 810-0044, Japan. tsaito@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0002-1279-6400
Masayuki IwanoDivision of Nephrology, Department of General Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Koichi MatsumotoThe University Research Center, General Science Institute, School of Medicine, Nihon University, Tokyo, Japan.
Tetsuya MitaraiDepartment of Nephrology and Blood Purification, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Hitoshi YokoyamaDivision of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.
Noriaki YoriokaHiroshima Kidney Organization, Hiroshima, Japan.
Shinichi NishiDivision of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan.
Ashio YoshimuraDivision of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Hiroshi SatoDivision of Nephrology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoru OgaharaDivision of Nephrology and Rheumatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Yoshie SasatomiDivision of Nephrology and Rheumatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Yasufumi KataokaDepartment of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
Shiro UedaUeda Clinic, Chiba, Japan.
Akio KoyamaProfessor Emeritus, Tsukuba University, Ibaraki, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan.
Enyu ImaiNakayamadera Imai Clinic, Hyogo, Japan.
Seiichi MatsuoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiko TominoProfessor Emeritus, Juntendo University, Tokyo, Japan.
Refractory Nephrotic Syndrome Study Group
Fukuoka University · JPJuntendo University · JPKanazawa Medical University · JPNagoya University · JPNihon University · JPTohoku University · JPUniversity of Tsukuba · JPKobe University · JPShowa University Fujigaoka Hospital · JPThe University of Tokyo · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe designed a prospective and randomized trial of mizoribine (MZR) therapy combined with prednisolone (PSL) for idiopathic membranous nephropathy (IMN) with steroid-resistant nephrotic syndrome (SRNS).

methodsPatients with IMN were divided into 2 groups, and MZR combined with PSL was administered for 2 years. PSL was initially prescribed at 40 mg/day and tapered. MZR was given once-a-day at 150 mg and 3-times-a-day at 50 mg each to groups 1 and 2. Serum MZR concentrations from 0 to 4 h after administration were examined within one month of treatment. The concentration curve and peak serum level (C

resultsAt 2 years, 10 of 19 patients (52.6 %) in group 1 and 7 of 18 patients (38.9 %) in group 2 achieved complete remission (CR). The time-to-remission curve using the Kaplan-Meier technique revealed an increase in the cumulative CR rate in group 1, but no significant difference between the groups. Meanwhile, there was a significant difference in C

conclusionAdministration of MZR once a day is useful when combined with PSL for treatment of IMN with SRNS. In addition, it is important to assay the serum concentration of MZR and to determine C

Indexed as

AdultAgedFemaleGlomerulonephritis, MembranousGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedNephrotic SyndromePrednisoloneProspective StudiesRibonucleosidesGlucocorticoidsImmunosuppressive AgentsmizoribinePrednisoloneRibonucleosidesEstimated serum concentration curveIdiopathic membranous nephropathyMizoribineOnce-a-day administrationSteroid-resistant nephrotic syndrome

Identifiers

PMID27783276
PMCPMC5698362
OpenAlexW2537374546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.